Centre hospitalier Sainte-Anne
Paris, 75014, France
Location status: Recruiting
NCT Number: NCT07054060
Carotid stenosis caused by atherosclerosis is a significant risk factor for ischemic stroke, accounting for up to 15% of all strokes and transient ischemic attacks. Randomized clinical trials (RCTs) have demonstrated the benefits of carotid endarterectomy (CEA) in reducing stroke risk in patients with severe symptomatic carotid stenosis. Carotid artery stenting (CAS) has been developed as an alternative to CEA, offering several potential advantages, such as avoiding local surgical complications. However, unlike CEA, CAS has not been compared to medical therapy in RCTs for symptomatic carotid stenosis.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Paris, 75014, France
Location status: Recruiting
CEA vs CAS Comparison:
Early RCTs conducted in the 2000s showed that CAS was associated with a higher risk of procedural stroke or death compared to CEA (8.9% vs 5.8%; RR 1.53, 95% CI 1.20-1.96, p=0.0006). However, CAS was found to be as effective as CEA in preventing recurrent ipsilateral strokes up to 10 years after treatment. Interestingly, an ancillary study of the ICSS trial showed that significantly more patients in the CAS group (50%) than in the CEA group (17%) had new ischemic lesions on diffusion-weighted MRI (DWI), suggesting that DWI might serve as a surrogate outcome measure for future carotid intervention trials.
Data Analysis and Recent Advances:
Individual pooled data analysis of RCTs indicated that CAS could be as safe and effective as CEA in patients under 70 years old. Recent advances in CAS technology, stenting techniques, antiplatelet therapy, and pre-treatment imaging have improved the periprocedural safety of CAS. Due to its ability to treat patients soon after a stroke, CAS has become increasingly used in routine clinical practice.
Study Objectives:
The question remains whether CAS is as safe as CEA in patients with recent symptomatic severe carotid stenosis. The study's objectives are:
Primary Objective:
To assess whether carotid stenting is non-inferior to carotid endarterectomy in preventing new ischemic lesions on DWI MRI, confirmed by a core lab.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Carotid endarterectomy is a surgical procedure used to reduce the risk of stroke due to carotid artery stenosis. During an endarterectomy, the surgeon opens the artery and removes the plaque.
Carotid artery stenting is an endovascular procedure in which a stent is deployed in the lumen of the carotid artery to treat narrowing of the carotid artery and reduce the risk of stroke.
Time frame: From 3 days before procedure to 7 days after procedure
Imaging endpoint : Proportion of patients having at least one new lesion on post-treatment Diffusion-Weigthed Imaging (DWI) MRI compared to pre-treatment DWI MRI and confirmed by a core lab.
The pre-treatment DWI MRI will be performed within 3 days before procedure. The post-treatment DWI MRI will be performed within 7 days after procedure.
Time frame: From 3 days before procedure to 7 days after procedure
Imaging endpoint : Number and size of new lesions on post-treatment MRI. The pre-treatment DWI MRI will be performed within 3 days before procedure. The post-treatment DWI MRI will be performed within 7 days after procedure.
Time frame: From 3 days before procedure to 7 days after procedure
Imaging endpoint : Proportion of patients having a new intracranial vessel occlusion on post-treatment MRI.
The pre-treatment DWI MRI will be performed within 3 days before procedure. The post-treatment DWI MRI will be performed within 7 days after procedure.
Time frame: From 3 days before procedure to 7 days after procedure
Imaging endpoint : Hemorrhagic transformation on post-treatment MRI. The pre-treatment DWI MRI will be performed within 3 days before procedure. The post-treatment DWI MRI will be performed within 7 days after procedure.
Time frame: From randomization to 30 days after procedure
Clinical endpoint : proportion of patients having any stroke or death during periprocedural period.
Time frame: From randomization to 30 days after procedure
Clinical endpoint : Proportion of patients having any stroke during periprocedural period.
Time frame: From randomization to 30 days after procedure
Clinical endpoint : Proportion of patients having any disabling or fatal stroke during periprocedural period.
Time frame: From randomization to 30 days after procedure
Clinical endpoint : Proportion of patients who died during periprocedural period.
Time frame: From randomization to 30 days after procedure
Clinical endpoint : Proportion of patients having a Transient ischemic attack during periprocedural period.
Time frame: From randomization to 30 days after procedure
Clinical endpoint : Proportion of patients having myocardial infarction during periprocedural period.
Time frame: From randomization to 30 days after procedure
Clinical endpoint : cervical or groin or radial hematoma, infection, arteriovenous fistula at puncture site, lower-limb arterial occlusion during periprocedural period.
Time frame: From randomization to 30 days after procedure
Clinical endpoint : Proportion of patients having cranial nerve injury during periprocedural period.
Time frame: From the date of the carotid artery stenting (CAS) or endarterectomy (CEA) procedure until the date of hospital discharge, assessed up to 30 days
Healthcare endpoint : number of days the patient stayed in the hospital stay
Time frame: From the date of patient randomization until the date of carotid artery stenting (CAS) or endarterectomy (CEA) procedure, assessed up to 15 days
Operational endpoint: number of days between the date at which the patient is randomized and the date at which the carotid artery stenting (CAS) or endarterectomy) is proceeded
Time frame: From 3 days before procedure to 7 days after procedure.
Clinical endpoint: Incidence of ischemic events among patients with confirmed new lesions on post-procedure DWI MRI (as verified by core lab assessment). The pre-treatment DWI MRI will be performed within 3 days before procedure. The post-treatment DWI MRI will be performed within 7 days after procedure.
Time frame: From 3 days before procedure to 7 days after procedure.
Imaging endpoint : Hemorrhagic transformation on post-treatment MRI. The pre-treatment DWI MRI will be performed within 3 days before procedure. The post-treatment DWI MRI will be performed within 7 days after procedure.
Contact information is provided by the study sponsor or research team.
Centre Hospitalier St Anne
Other
Acronym: EVA3S-2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06700005
Alexia, Aphasia
Washington D.C., District of Columbia, United States
View Trial DetailsNCT04991519
Alexia, Aphasia
Washington D.C., District of Columbia, United States
View Trial DetailsNCT06123767
Apraxias, Arterial Occlusive Diseases
Wroclaw, Lower Silesian Voivodeship, Poland
View Trial DetailsNCT04957225
Aphasia, Apraxia of Speech
Stockholm, Sweden
View Trial Details